UK investments in global infectious disease research 1997–2010: a case study Michael G Head, PGDip, Joseph R Fitchett, MSc, Mary K Cooke, MSc, Fatima B Wurie, BSc, Andrew C Hayward, MD, Rifat Atun, FRCP The Lancet Infectious Diseases Volume 13, Issue 1, Pages 55-64 (January 2013) DOI: 10.1016/S1473-3099(12)70261-X Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 1 Sources and numbers of studies screened ESRC=Economic and Social Research Council. BBSRC=Biotechnology and Biological Sciences Research Council. The Lancet Infectious Diseases 2013 13, 55-64DOI: (10.1016/S1473-3099(12)70261-X) Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 2 Association between investment and DALYs Association between investment in specific infection and DALYs in 2004 (Spearman's correlation coefficient [r] 0·5908 [A]). Investment in specific infection and DALYs in 2008 (r 0·3688; p=0·0999 [B]). Investment in disease system and DALYs in 2004 (r 0·8810 [C]). Investment in disease system and DALYs in 2008 (r 0·8333) using a logarithmic scale (D). DALYs=disability-adjusted life-years. HPV=human papillomavirus. The Lancet Infectious Diseases 2013 13, 55-64DOI: (10.1016/S1473-3099(12)70261-X) Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 3 Distribution of cumulative funding by disease system and breakdown by research pipeline (A), and proportional breakdown of research pipeline within disease system (B) The Lancet Infectious Diseases 2013 13, 55-64DOI: (10.1016/S1473-3099(12)70261-X) Copyright © 2013 Elsevier Ltd Terms and Conditions